| Abstrakt: |
A recent study conducted at the University of Sao Paulo explored the impact of bradykinin, an inflammation-related peptide, on neural progenitor cells (NPCs) carrying mutations associated with Alzheimer's disease (AD). The researchers found that bradykinin promoted immune responses and increased the expression of genes related to microglia-mediated neuroinflammation. In contrast, inhibiting bradykinin activity resulted in a reduction of AD-related anomalies in the NPCs. These findings suggest that modulating bradykinin activity may have potential therapeutic implications for slowing the progression of Alzheimer's disease. [Extracted from the article] |
